ECIRMedicalCommunications

Advancing Medicine with Dynamic Scientific Communication

[AstraZenecaUS @AstraZenecaUS]

Today we announced results from two subgroup analyses of the TWILIGHT trial in high-risk coronary patients with diabetes undergoing percutaneous coronary intervention (PCI) and in patients undergoing complex PCI. Learn more about the data: https://t.co/prikMYZi93 #ACC20 #WCCardio

[ECIRMedicalCommunications @ECIRMedCom]

Meet Sabrina McGuigan, Director of Strategic Services at ECIR Medical Communications! #employeefeature #leadership #strategy #strategicservices #industry

[ECIRMedicalCommunications @ECIRMedCom]

Today is #WorldHeartDay! Cardiovascular diseases make up 31% of all global deaths according to the World Health Organization (WHO). We at ECIR Medical Communications are happy to work with our clients to advance medicine and improve cardiovascular outcomes.
#ACCCVT

[ECIRMedicalCommunications @ECIRMedCom]

#ARS and #AAOHNSF met last week in #NewOrleans for their annual meetings! We were onsite supporting our clients with congress strategy, insights, and scientific content development, all while learning about the latest research and findings in #Rhinology and #Otolaryngology!

[ECIRMedicalCommunications @ECIRMedCom]

Yesterday was World Alzheimer’s Day. According to the Alzheimer’s Association, 47 million people are living with Alzheimer’s disease worldwide. Alzheimer's disease has no current cure, but treatments for symptoms are available and the research continues. Help us raise awareness!

[ECIRMedicalCommunications @ECIRMedCom]

We are onsite at #HFSA2019 engaging with key thought leaders in the field of heart failure! For more information about how we advance medicine through dynamic scientific communications please visit our website https://t.co/tOUe8APJZM or feel free to contact us at [email protected]

[ECIRMedicalCommunications @ECIRMedCom]

@WilsonTangMD Thank you!

[ECIRMedicalCommunications @ECIRMedCom]

@HFSA Curious as to when the full program will be posted!!

[Marat Fudim, MD MHS @FudimMarat]

Some news today:

Dapagliflozin met primary endpoint in Phase III DAPA-HF trial for treatment of HFrEF. This was a dedicated HF trial. Significant reduction in combined endpoint of CV death and Worsening HF. @texhern ⁦@robmentz⁩ ⁦@_adevore⁩ https://t.co/4iwyhA55gB

[Endocrine Today @EndocrineToday]

VIDEO: SGLT inhibitors for type 1 diabetes require more study https://t.co/OOEQn3bU9t @TheAACE #AACE2019

[ECIRMedicalCommunications @ECIRMedCom]

Our ECIR team is excited to attend #AACE2019 in Los Angeles this weekend! We are looking forward to an exciting and innovative weekend of educational sessions, networking, and events.

We are ready to #GetInspired!